Literature DB >> 24751552

Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents.

Mahesh B Palkar1, Anuj S Singhai2, Pradeepkumar M Ronad2, A H M Vishwanathswamy3, Thippeswamy S Boreddy4, Veeresh P Veerapur4, Mahamadhanif S Shaikh5, Rajesh A Rane5, Rajshekhar Karpoormath6.   

Abstract

A novel series of 5-[2-(2,6-dichlorophenylamino)benzyl]-3-(substituted)-1,3,4-oxadiazol-2(3H)-thione (4a-k) derivatives have been synthesized by the Mannich reaction of 5-[2-(2,6-dichlorophenylamino)benzyl]-1,3,4-oxadiazol-2(3H)-thione (3) with an appropriately substituted primary/secondary amines, in the presence of formaldehyde and absolute ethanol. Structures of these novel compounds were characterized on the basis of physicochemical, spectral and elemental analysis. The title compounds (4a-k) were screened for in vivo acute anti-inflammatory and analgesic activities at a dose of 10mg/kg b.w. Compound 4k exhibited the most promising and significant anti-inflammatory profile while compounds 4a, 4d, 4e, 4i, and 4j showed moderate to good inhibitory activity at 2nd and 4thh, respectively. These compounds were also found to have considerable analgesic activity (acetic acid induced writhing model) and antipyretic activity (yeast induced pyrexia model). In addition, the tested compounds were also found to possess less degree of ulcerogenic potential as compared to the standard NSAIDs. Compounds that displayed promising anti-inflammatory profile were further evaluated for their inhibitory activity against cyclooxygenase enzyme (COX-1/COX-2), by colorimetric COX (ovine) inhibitor screening assay method. The results revealed that the compounds 4a, 4e, 4g and 4k exhibited effective inhibition against COX-2. In an attempt to understand the ligand-protein interactions in terms of the binding affinity, docking studies were performed using Molegro Virtual Docker (MVD-2013, 6.0) for those compounds, which showed good anti-inflammatory activity. It was observed that the binding affinities calculated were in agreement with the IC50 values.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  1,3,4-Oxadiazole; Analgesic; Anti-inflammatory; Cyclooxygenase (COX); Diclofenac; Docking; Mannich base; NSAIDs; Ulcerogenic

Mesh:

Substances:

Year:  2014        PMID: 24751552     DOI: 10.1016/j.bmc.2014.03.043

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Novel 1,3,4-Oxadiazole Derivatives of Pyrrolo[3,4-d]Pyridazinone Exert Anti-Inflammatory Activity without Acute Gastrotoxicity in the Carrageenan-Induced Rat Paw Edema Test.

Authors:  Marta Szandruk-Bender; Anna Merwid-Ląd; Benita Wiatrak; Maciej Danielewski; Stanisław Dzimira; Danuta Szkudlarek; Łukasz Szczukowski; Piotr Świątek; Adam Szeląg
Journal:  J Inflamm Res       Date:  2021-11-02

2.  N-Aryl iminochromenes inhibit cyclooxygenase enzymes via π-π stacking interactions and present a novel class of anti-inflammatory drugs.

Authors:  Ha Thi Nguyen; Thien-Y Vu; A Vijay Kumar; Vo Nguyen Huy Hoang; Pham Thi Ngoc My; Prashant S Mandal; Vinay Bharadwaj Tatipamula
Journal:  RSC Adv       Date:  2021-09-02       Impact factor: 4.036

3.  Modifying tetramethyl-nitrophenyl-imidazoline with amino acids: design, synthesis, and 3D-QSAR for improving inflammatory pain therapy.

Authors:  Xueyun Jiang; Yuji Wang; Haimei Zhu; Yaonan Wang; Ming Zhao; Shurui Zhao; Jianhui Wu; Shan Li; Shiqi Peng
Journal:  Drug Des Devel Ther       Date:  2015-04-22       Impact factor: 4.162

4.  New 1,3,4-Oxadiazole Derivatives of Pyridothiazine-1,1-Dioxide with Anti-Inflammatory Activity.

Authors:  Teresa Glomb; Benita Wiatrak; Katarzyna Gębczak; Tomasz Gębarowski; Dorota Bodetko; Żaneta Czyżnikowska; Piotr Świątek
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

5.  Novel 1,3,4-Oxadiazole Derivatives of Pyrrolo[3,4-d]pyridazinone Exert Antinociceptive Activity in the Tail-Flick and Formalin Test in Rodents and Reveal Reduced Gastrotoxicity.

Authors:  Marta Szandruk-Bender; Benita Wiatrak; Łukasz Szczukowski; Piotr Świątek; Maria Rutkowska; Stanisław Dzimira; Anna Merwid-Ląd; Maciej Danielewski; Adam Szeląg
Journal:  Int J Mol Sci       Date:  2020-12-18       Impact factor: 5.923

6.  New N-Substituted-1,2,4-triazole Derivatives of Pyrrolo[3,4-d]pyridazinone with Significant Anti-Inflammatory Activity-Design, Synthesis and Complementary In Vitro, Computational and Spectroscopic Studies.

Authors:  Łukasz Szczukowski; Edward Krzyżak; Benita Wiatrak; Paulina Jawień; Aleksandra Marciniak; Aleksandra Kotynia; Piotr Świątek
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

7.  Synthesis, Anticancer Activity and Molecular Docking Studies of Novel N-Mannich Bases of 1,3,4-Oxadiazole Based on 4,6-Dimethylpyridine Scaffold.

Authors:  Małgorzata Strzelecka; Teresa Glomb; Małgorzata Drąg-Zalesińska; Julita Kulbacka; Anna Szewczyk; Jolanta Saczko; Paulina Kasperkiewicz-Wasilewska; Nina Rembiałkowska; Kamil Wojtkowiak; Aneta Jezierska; Piotr Świątek
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

8.  Diclofenac N-Derivatives as Therapeutic Agents with Anti-Inflammatory and Anti-Cancer Effect.

Authors:  Alberto Galisteo; Fatin Jannus; Amalia García-García; Houssam Aheget; Sara Rojas; José A Lupiañez; Antonio Rodríguez-Diéguez; Fernando J Reyes-Zurita; José F Quílez Del Moral
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.